What is a PDUFA date?

A PDUFA (Prescription Drug User Fee Act) date is the FDA's target action date for making a regulatory decision on a drug application (NDA or BLA). These dates are critical binary events for biotech investors as they can cause significant stock price movements of 20-70% in either direction.

How does ODIN predict FDA approvals?

ODIN v14 is a 51-feature L2 Ridge regression trained on 2,210 historical FDA PDUFA events (705 CRLs, 32.0% base rate) from 2015-2026. It analyzes signals across regulatory designations, manufacturing risk, therapeutic area history, sponsor experience, clinical trial design, and FDA era effects to produce a calibrated approval probability. It achieves 0.9363 AUC on walk-forward testing with consistent yearly performance (0.89-0.94).

What is the PDUFA runup strategy?

The PDUFA runup strategy is a validated trading approach based on analysis of 934 PDUFA events showing that biotech stocks systematically appreciate in the 25 trading days before an FDA decision date. The strategy enters at T-25 and exits at T-5 or T-7 depending on ODIN tier, capturing the anticipatory move without holding through the binary event.

ODIN assigns each FDA catalyst to one of four conviction tiers: TIER_1 (85%+ approval probability, full position), TIER_2 (65-85%, half position), TIER_3 (40-65%, small speculative or avoid), and TIER_4 (below 40%, no trade). The tiers drive position sizing and risk management for the PDUFA runup trading strategy.

What is a Complete Response Letter (CRL)?

A Complete Response Letter (CRL) is an FDA notification that the agency cannot approve a drug application in its current form. CRLs cite deficiencies in manufacturing (CMC), clinical efficacy, or safety data. Historically, 32.3% of PDUFA decisions result in CRLs. ODIN's strongest signal is prior CRL history, which carries a -3.21 logit penalty.

When was ETON Pharmaceuticals topical baclofen PDUFA date?

ETON Pharmaceuticals topical baclofen had a PDUFA target action date of February 25, 2026. The FDA approved the drug on schedule on February 25, 2026. ODIN scored it at 85.5% TIER_1, and the stock rose +14.7% during the runup from T-25 to T-7. Track live PDUFA status and ODIN AI approval probability (AUC 0.9363) at pdufa.bio/eton-pdufa.

What is the Vanda Pharmaceuticals PDUFA date in February 2026?

Vanda Pharmaceuticals (VNDA) had a PDUFA target action date of February 21, 2026 for Bysanti (milsaperidone) for schizophrenia. The FDA approved the drug one day early on February 20, 2026. ODIN scored it at 89.7% TIER_1, and the stock rose +44% after hours. Track live PDUFA status and ODIN AI approval probability (AUC 0.9363) at pdufa.bio/calendar.

What are the upcoming PDUFA dates for February 2026?

Key February 2026 PDUFA dates include ETON Topical Baclofen (Feb 25, APPROVED), VNDA Bysanti (Feb 21, APPROVED), OTSKF INQOVI+Venetoclax for AML (Feb 25), REGN Dupixent for allergic fungal rhinosinusitis (Feb 28, APPROVED), and ASND Navepegritide for anemia of CKD (Feb 28). The full Q1 2026 calendar with ODIN AI biotech catalyst scores is available at pdufa.bio/pdufa-calendar-2026.

What FDA approvals are expected in Q1 2026?

Q1 2026 features approximately 10-12 FDA PDUFA decisions, including high-profile oncology, immunology, and endocrinology catalysts. Key names include BMY deucravacitinib for UC (March 6), LLY orforglipron for diabetes (April 10), RCKT Kresladi gene therapy (March 28), and LNTH Ga68-edotreotide for NET imaging (March 29). Track all dates with ODIN probability scores at pdufa.bio.

What is Ryoncil (remestemcel-L) used for?

Ryoncil (remestemcel-L) is an allogeneic mesenchymal stromal cell (MSC) therapy being developed for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients. GVHD is a serious complication of hematopoietic stem cell transplantation (HSCT) where donor immune cells attack recipient tissues. The therapy harnesses the immunomodulatory properties of MSCs to reduce inflammation and promote tissue repair.

Why was Ryoncil previously rejected by the FDA, and what changed in the resubmission?

The initial BLA received a Complete Response Letter (CRL) due to concerns regarding manufacturing variability, clinical efficacy consistency, and long-term follow-up data on treated patients. In the resubmission, Mesoblast provided additional manufacturing controls, expanded patient safety database, longer-term efficacy follow-up from earlier trials, and clarified the mechanism of MSC action. The FDA granted Priority Review for the resubmission, suggesting that the new data may have addressed the prior deficiencies.

What does pediatric designation mean for Ryoncil's approval odds?

Ryoncil received Pediatric Priority Review Voucher (PPRV) eligibility and orphan drug designation, both of which reduce regulatory burden and increase FDA flexibility. Pediatric diseases with unmet medical need and limited treatment alternatives historically see higher approval rates (75%+ for cell therapies in rare pediatric conditions). These designations materially boost approval probability compared to adult-indication submissions.

MESO Ryoncil PDUFA: Remestemcel-L for SR-aGVHD — ODIN Resubmission Analysis

CATALYST STATUS: UPCOMING RESUBMISSION

Ryoncil (remestemcel-L) PDUFA decision expected March 2026. This is a resubmission following a prior Complete Response Letter (CRL). ODIN classifies this as a complex, higher-risk catalyst with significant efficacy and manufacturing variability considerations. TIER_2 / TIER_3 territory.

Overview: MESO, Ryoncil & SR-aGVHD

Ticker: MESO (Mesoblast Limited, ASX-listed, ~$200M market cap).

Therapeutic: Ryoncil (remestemcel-L) — an allogeneic mesenchymal stromal cell (MSC) therapy, ex vivo expanded from bone marrow.

Indication: Steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients. SR-aGVHD is a life-threatening complication of hematopoietic stem cell transplantation (HSCT) where donor immune cells attack recipient tissues and do not respond to standard corticosteroid therapy.

Unmet Medical Need: High. Pediatric SR-aGVHD has limited approved treatment options. Standard of care includes high-dose corticosteroids and CNI (calcineurin inhibitors), but >50% of patients fail to respond or experience severe side effects. Mortality rates in refractory GVHD exceed 80% within 2 years.

PDUFA Target Date: March 2026 (Standard or Priority Review timeline; review type TBD).

Regulatory History: Initial BLA submission received Complete Response Letter (CRL) in 2023. Resubmission filed in 2025 with additional manufacturing and clinical data.

Mesenchymal Stromal Cell (MSC) Therapy: Mechanism & Promise

Mesenchymal stromal cells (MSCs) are multipotent bone marrow-derived cells with immunomodulatory and tissue-repairing properties. Remestemcel-L is a well-characterized allogeneic MSC product—expanded ex vivo and then infused systemically into GVHD patients.

The proposed mechanism of action includes: (1) suppression of donor T cell proliferation and pro-inflammatory cytokine production (IL-2, TNF-α, IFN-γ); (2) upregulation of regulatory T cells (Tregs); (3) direct tissue repair via anti-apoptotic signaling and growth factor secretion; (4) enhanced host immune reconstitution. This multi-modal approach differs fundamentally from immunosuppressive drugs and may preserve graft-versus-leukemia (GVL) effect while controlling GVHD.

Cell therapy is inherently complex from manufacturing, potency, and safety perspectives. Variability in MSC lot-to-lot potency, viability, and inflammatory profile has historically been a key FDA concern in cell therapy submissions.

Clinical Data & the Prior CRL

Initial BLA (2023): Mesoblast submitted a BLA based on Phase 2 efficacy data and early follow-up. The application received a Complete Response Letter due to:

Manufacturing Variability: FDA raised questions about lot-to-lot consistency of potency assays. The in vitro potency assay (TIM assay) did not fully correlate with clinical outcomes, raising concerns about whether the assay adequately predicted in vivo efficacy.
Efficacy Signals in Pediatrics: The Phase 2 trial enrolled both pediatric and adult patients. Pediatric-specific efficacy and safety data were limited. FDA requested more granular pediatric subgroup analysis and longer follow-up.
Long-Term Safety Follow-Up: Limited long-term surveillance data on MSC recipients (tumor formation, ectopic growth, graft rejection). Cell therapy products require robust long-term safety databases.
Mechanism Clarification: FDA requested additional studies clarifying the in vivo mechanism, biodistribution, and potential off-target effects.

Resubmission (2025): Mesoblast responded with:

Refined potency assay (improved lot-to-lot consistency and clinical correlation)
Expanded pediatric-specific efficacy and safety data from ongoing follow-up
Long-term follow-up data on treated patients (3+ years in some cases)
Mechanism studies detailing MSC biodistribution and functional impact

ODIN's Resubmission Risk Assessment

Ryoncil represents a complex resubmission case with multiple risk vectors. ODIN classifies this as TIER_2/TIER_3 (approval probability 55-75% range) due to:

Prior CRL History (-15%): Resubmissions following CRLs have lower approval rates (60-70%) than first-time submissions (75%+). The prior deficiencies must be comprehensively addressed; partial responses increase rejection risk.
Cell Therapy Complexity (-10%): Cell-based products face higher manufacturing and potency variability risks. FDA scrutiny of lot-to-lot consistency and clinical correlation is intense. One outlier lot or potency issue can delay or derail approval.
Pediatric-Specific Data Gap (-8%): Pediatric GVHD is rare; trial populations are small. Limited pediatric-specific efficacy data increases uncertainty. FDA may require larger pediatric cohorts or longer follow-up.
Long-Term Safety Concerns (-7%): Allogeneic cell therapies raise long-term questions (tumor formation, immune sensitization). 3+ year follow-up is improving, but longer surveillance data strengthen approval odds.
Competitive Pressure (+5%): Limited competing therapies in SR-aGVHD (mostly off-label, second-line immunosuppressants). This unmet need supports approval.
Orphan Designation & PPRV Eligibility (+6%): Pediatric Priority Review Voucher (PPRV) and Orphan Drug Designation reduce FDA bureaucratic burden. These encourage more favorable regulatory interpretation.
Mechanism Differentiation (+4%): MSC mechanism is novel and aligns with emerging immunology. No competing MSC therapies approved for GVHD. Market opportunity is defensible.
Manufacturing Responsiveness (+3%): Mesoblast invested significantly in refining potency assay. If FDA finds the new assay well-designed and reproducible, manufacturing concerns ease.

Net: ODIN assigns 62-68% approval probability (TIER_2 midpoint) pending detailed review of resubmission dossier. This reflects the complexity of cell therapy and prior CRL history, balanced against strong unmet need and regulatory designations.

Critical Success Factors for March 2026 PDUFA

Potency Assay Acceptance: FDA must find the refined TIM assay (or alternative potency method) scientifically sound and clinically predictive. If FDA reopens questions on assay validity, approval timeline extends 6+ months.
Pediatric Efficacy Confirmation: Pediatric subgroup data must show consistent response rates (generally >40% response in SR-aGVHD is considered clinically meaningful). Below-threshold pediatric response = major headwind.
Manufacturing Clean-Up: Zero lot-to-lot failures or potency outliers in new data package. One poor lot = FDA concerns re-opened.
Long-Term Safety Clearance: No new safety signals in 3+ year follow-up (malignancy, immunosuppression, graft failure). Clean long-term data substantially improves approval odds.
Expedited Review Slot: If FDA grants Priority Review (not yet confirmed), March timeline feasible. Standard Review might extend to April/May.

📊 Live Options Flow Intelligence

Real-time options market signals powered by ODIN × FinBrain. Tracks put/call positioning, whale bias, and unusual options activity around the PDUFA catalyst window.

📊OPTIONS & FLOW

Loading options signals...

Regulatory Designations & Precedent

Ryoncil has secured two important designations:

Orphan Drug Designation (ODD): Granted for SR-aGVHD in pediatrics. Provides 7-year marketing exclusivity, reduced regulatory fees, and FDA incentive to accelerate review. ODD holders see slightly higher approval rates (72%+) than non-ODD products.
Pediatric Priority Review Voucher (PPRV) Eligibility: If approved, Mesoblast can redeem a PPRV to accelerate review of a future program. This creates strategic incentive for FDA to approve Ryoncil (demonstrates pediatric program support). PPRV-eligible programs see ~5% approval rate uplift.

Historically, cell therapies with orphan designation in rare pediatric diseases (e.g., inherited metabolic disorders, rare immunodeficiencies) have achieved 70-75% approval rates. Ryoncil is broadly aligned with this category.

Investor Considerations & Risk Factors

Upside Scenarios: Approval in March 2026 would validate Mesoblast's MSC platform, open pediatric SR-aGVHD market (~500-800 pediatric patients/year in US + EU), and potentially unlock label extensions into adult GVHD or other inflammatory conditions. MESO stock could appreciate 30-50% on approval.

Downside Scenarios: CRL on resubmission (15-20% probability) would extend timeline 12-18 months, require more data, and validate concerns about manufacturing/efficacy. This could trigger 40-60% stock decline. Partial approval (e.g., adult GVHD only, not pediatric) would reduce market opportunity.

Binary Event: Ryoncil approval is a significant binary for MESO, representing one of the company's most advanced programs. Portfolio concentration risk is notable.

Related Resources & Ongoing Monitoring

Track MESO Ryoncil and other March 2026 PDUFA catalysts on the full calendar.
Learn about ODIN v2.1 and how it scores complex resubmissions and cell therapy programs.
Understand PDUFA dates and regulatory timelines for resubmissions.
Access real-time ODIN scores and alerts for upcoming catalysts.